Published in Cancer Weekly, July 23rd, 2002
The study results showed that MLN341 stabilized or reduced myeloma (M) protein, a primary marker of cancer burden, in the majority of study participants, with manageable and predictable side effects. In addition, the majority of patients did not experience disease progression during the 24 week study. The results were announced at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.